Revium Rx. operates as a pre-clinical stage biopharmaceutical company focused on the development of nanoparticle-based therapies in the United States. The company develops lipid-based platforms for a variety of uses including antimicrobial resistance and solid tumors. The company specializes in infectious diseases, including antibiotic-resistant infections, solid tumors and vaccination. The company also develops nano-liposomal particles (NLP) based pharmaceutical candidates. It develops nanoparticles-based formulation of a potent antibiotic; novel adjuvant for cancer therapies: and novel immunization based on liposomal protein-loaded technology. The company was formerly known as Revium Recovery Inc. and changed its name to Revium Rx. in December 2024. Revium Rx. was founded in 1997 and is based in Herzliya, Israel.